Research Article

Unveiling the Hidden Burden: Estimating All-Cause Mortality Risk in Older Individuals with Type 2 Diabetes

Table 2

Univariate and multivariate logistic regression analyses of the training set.

Univariate logistic regressionMultivariate logistic regression
CharacteristicOR (95% CI) valueOR (95% CI) value

Age (years)1.16 (1.13-1.20)<0.0011.16 (1.12-1.19)<0.001
Sex, (%)
 MaleRef.Ref.
 Female0.60 (0.45-0.80)<0.0010.58 (0.41-0.80)0.001
EGFR1.00 (1.00-1.01)0.0311.00 (1.00-1.01)0.014
Albumin0.87 (0.84-0.91)<0.0010.88 (0.84-0.92)<0.001
Race, (%)
 Non-Hispanic WhiteRef.Ref.
 Non-Hispanic Black1.00 (0.65, 1.55)0.999NANA
 Other Hispanic1.05 (0.63, 1.74)0.851NANA
 Other races1.13 (0.78, 1.63)0.515NANA
Education level, (%)
 Less than high schoolRef.Ref.
 High school diploma or GED0.87 (0.60, 1.24)0.865NANA
 More than high school0.79 (0.54, 1.17)0.792NANA
Smoking status, (%)
 Never smokerRef.Ref.
 Ever smoker1.13 (0.77, 1.66)0.528NANA
 Current smoker0.99 (0.65, 1.49)0.952NANA
Drinking status, (%)
 NondrinkerRef.Ref.
 Low-to-moderate drinker1.01 (0.75, 1.36)0.959NANA
 Heavy drinker0.91 (0.55, 1.51)0.714NANA
BMI (kg/m2), (%)
 <25.00Ref.Ref.
 25.00–29.990.70 (0.48-1.01)0.0510.82 (0.55-1.23)0.344
 ≥30.00.75 (0.49, 1.16)0.2550.78 (0.53, 1.20)0.297
PIR, (%)
 <1.0Ref.Ref.
 1.0-3.01.30 (0.81, 2.09)0.959NANA
 >3.01.29 (0.91, 1.85)0.714NANA
Medication use1.07 (0.82, 1.39)0.641NANA
Hypertension0.94 (0.69, 1.28)0.685NANA
CVD0.80 (0.54, 1.21)0.291NANA
Antihyperlipidemic drug1.42 (1.06-1.90)0.0191.18 (0.86-1.62)0.316
Lymphocyte1.03 (0.96, 1.10)0.392NANA
AST1.01 (1.00-1.02)0.0301.01 (1.00-1.02)0.089
Total cholesterol1.00 (0.99, 1.00)0.942NANA
Uric acid1.07 (0.98, 1.18)0.147NANA
Triglyceride1.00 (0.99, 1.00)0.813NANA
ALT0.99 (0.98, 1.01)0.782NANA
High-density lipoprotein1.01 (0.99, 1.02)0.389NANA
Hosmer-Lemeshow test0.542

Abbreviations: PIR: poverty-to-income ratio; BMI: body mass index; CVD: cardiovascular disease; EGFR: estimated glomerular filtration rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase.